US Edition
News from targetedonc.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top targetedonc.com News
Cancer(MedPage Today) -- BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall survival (OS) in high-risk early breast cancer, data reported here showed.
Patients who received...See the Story
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
80% Center coverage: 5 sources
Science · United StatesScientists have discovered how leukemia cells outsmart a leading treatment and may have found a way to stop them. Scientists from Rutgers Health and collaborating institutions have uncovered why a widely used leukemia drug stops working for many patients and have identified a possible method to reverse that resistance. The research team found that a [...]See the Story
Scientists Discover How Leukemia Cells “Cheat Death” and Evade Treatment
75% Center coverage: 4 sources
United States · United StatesOn Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. The Blenrep approval is supported by data from the pivotal DREAMM-7 phase 3 trial. Multiple myeloma is the third most common blood cancer globally and is …See the Story
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - GSK (NYSE:GSK)
100% Center coverage: 1 sources
